Meristem Therapeutics
This article was originally published in Start Up
Executive Summary
France's Meristem Therapeutics, spun out of seed producer Groupe Limagrain, is using transgenic plants to produce commercial quantities of purified protein-based pharmaceuticals. It hopes that the success of its phase II product, lipase, will help convince an as-yet skeptical pharmaceutical industry of the value--both in terms of safety, cost and efficiency--of plant-derived therapeutics.
You may also be interested in...
Protein Production Start-Ups
Should a disruptive protein production technology emerge, the current interest in developing large-molecule therapeutics assures there would be many takers.
Protein Production Start-Ups
Should a disruptive protein production technology emerge, the current interest in developing large-molecule therapeutics assures there would be many takers.
Protein Harvest
Genetic engineering is giving a new meaning to the term "manufacturing plant" as the biotechnology industry looks to potatoes, corn, tobacco, and other crops to provide cheap manufacturing sources for therapeutic The lack of capacity for the cost-effective manufacture of protein-based pharmaceuticals will soon cause a significant bottleneck at pharmaceutical companies, one that threatens to impede the progress of therapeutics at all stages of development, from the preclinical stage to commercialization. Today, companies are faced with the limited options of either queuing up for outsourced manufacturing, or investing hundreds of millions of dollars in their own production capacity well before they know that a product will succeed. A bumper crop of new companies is therefore poised to take advantage of the manufacturing capabilities of plants that have been genetically engineered to produce human proteins.